Alkermes Incorporated

Alkermes, Inc. is applying the tools of biotechnology to the development of sophisticated proprietary drug delivery systems. Alkermes is developing product candidates based on its independent drug delivery technologies: ProLease(R), which is designed to enable single injections lasting a few days to several months to be made of proteins or peptides otherwise given by more frequent injection; Cereport(TM) (formerly known as RMP-7(TM)), which is designed to enable increased drug delivery to the brain by transiently opening the blood-brain barrier; and Medisorb(R), which extends Alkermes' technology for injectable sustained release and is designed for more traditional small molecule pharmaceutical compounds.

Contact Details: 64 Sidney Street Cambridge MA 02139-4234 United States of America Tel: 617 494 0171 Fax: 617 494 9263 Email: financial@alkermes.com WWW: www.alkermes.com/

Loading...

Recent Publications by Alkermes Incorporated:
Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities. OBJECTIVE: To determine the prevalence of abnormal glucose homeostasis and...	3rd October, 2009	Division of Endocrinology, Children's Memorial Hospital (W.B.) and the	J Pediatr. 2009 Sep 29. DOI Direct Link
A link between adolescent nicotine metabolism and smoking topography. Adult slow nicotine metabolizers have lower smoke exposure, carbon...	26th June, 2009	National Institute on Drug Abuse Intramural Research Program, National	Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1578-83. DOI Direct Link
Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats. Opioid receptor antagonism has been shown to attenuate behavioral and...	6th June, 2009	Department of Life Sciences and Toxicology, Alkermes, Inc., USA.	Addict Biol. 2009 Sep;14(4):408-18. Epub 2009 Jun 1. DOI Direct Link
Implementation of a low-cost Interim 21CFR11 compliance solution for laboratory environments. In the recent past, compliance with 21CFR11 has become a major buzzword...	18th October, 2008	Alkermes Inc. 88 Sidney Street Cambridge MA 02139 USA.	J Autom Methods Manag Chem. 2003;25(3):69-71. DOI Direct Link
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. A monthly extended-release formulation of the opioid antagonist naltrexone...	7th August, 2008	Department of Life Sciences and Toxicology, Alkermes, Inc., 88 Sidney St.,	Pharmacol Biochem Behav. 2008 Jun;89(4):515-22. Epub 2008 Feb 11. DOI Direct Link
→View more Alkermes Incorporated research publications.

BioNews Results for Alkermes Incorporated:
Alkermes Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference	Your Story:  Nov 10 2009 9:12PM Matching: alkermes
Alkermes Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference	Your Story:  Nov 10 2009 9:12PM Matching: alkermes
Alkermes Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference	Business Wire UK:  Nov 10 2009 9:19PM Matching: alkermes
Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference	Pharma Live:  Nov 10 2009 11:06PM Matching: alkermes
Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference	Reuters:  Nov 10 2009 10:49PM Matching: alkermes
Promote your company here: BioNewsCast - Press Release Distribution	→View more Alkermes Incorporated news.

Alkermes Incorporated Clinical Trials:
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

Alkermes Incorporated Patents:
US Patent No.	Title
6495164	Preparation of injectable suspensions having improved injectability
6667061	Preparation of injectable suspensions having improved injectability
6703477	Acid end group poly(D,L-lactide-co-glycolide) copolymers with high glycolide content
6705757	Method and apparatus for preparing microparticles using in-line solvent extraction
6713087	Method of producing submicron particles of a labile agent and use thereof
→View more Alkermes Incorporated patents.

Alkermes Incorporated (ALKS) Financial information Links from Barchart
ALKS Quote from from Barchart.com
ALKS Chart from from Barchart.com
ALKS Profile from from Barchart.com
ALKS Opinion from from Barchart.com
→View more Alkermes Incorporated finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 26 individuals from Alkermes Incorporated using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 487 times since April 2007, the link to the organisation's website has been followed 79 times

Recent Search Terms used to find this page: Alkermes Inc. 64 sidney street | alkermes toxicology | alkermes pharma | prolease alkermes | alkermes patents | alkermes inc. cereport | alkermes inc contact details | Alkermes toxicology | alkermes cambridge | alkermes cambridge | .

Search for more companies in Cambridge

Search for more companies in MA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Alkermes Incorporated